These data underscore the critical role of PP2A signaling in AKR1B10-mediated metastasis and highlight the potential of a pharmacological PP2A activator as a therapeutic strategy against AKR1B10-deficient CRC metastasis. This evidence concerns the gene PTPA and colorectal carcinoma.